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A B S T R A C T
Introduction: Resistance to second-line tuberculosis drugs is common, but slow to diagnose with
phenotypic drug sensitivity testing. Rapid molecular tests speed up diagnosis, but can only detect limited
mutations. Whole genome sequencing (WGS) of culture isolates can generate a complete genetic drug
resistance proﬁle, but is delayed by the initial culture step. In the case presented here, successful WGS
directly from sputum was achieved using targeted enrichment.
Case report: A 29-year-old Nigerian woman was diagnosed with tuberculosis. Xpert MTB/RIF and Hain line
probe assays identiﬁed rpoB and inhA mutations consistent with rifampicin and intermediate isoniazid
resistance, and a further possible mutation conferring ﬂuoroquinolone resistance. WGS directly from
sputum identiﬁed a further inhA mutation consistent with high-level isoniazid resistance and conﬁrmed
the absence of ﬂuoroquinolone resistance. Isoniazid was stopped, and the patient has completed
18 months of a ﬂuoroquinolone-based regimen without relapse.
Discussion: Compared to rapid molecular tests (which can only examine a limited number of mutations)
and WGS of culture isolates (which requires a culture step), WGS directly from sputum can quickly
generate a complete genetic drug resistance proﬁle. In this case, WGS altered the clinical management of
drug-resistant tuberculosis and demonstrated potential for guiding individualized drug treatment where
second-line drug resistance is common.
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Drug-resistant tuberculosis (DR-TB) is a major risk to global
tuberculosis (TB) control. Multidrug-resistant TB (MDR-TB) was
responsible for 480 000 new cases and 190 000 deaths in 2014.
Globally, 30% of MDR-TB cases are resistant to either ﬂuoroqui-
nolones or aminoglycosides, which are the main second-line drugs.
Although the incidence of DR-TB has been stable over time, this is
due to a low diagnosis rate and high fatality rate of 40%. Only 4.9%
of notiﬁed TB patients underwent drug resistance testing in 2009,
although this increased to 30% by 2015.* Corresponding author at: Division of Infection and Immunity, University College
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(http://creativecommons.org/licenses/by/4.0/).As more MDR-TB is diagnosed and treated with second-line
drugs, there is now increased emphasis on detecting resistance to
these drugs. MDR-TB is often treated with standardized drug
regimens, including the 9-month regimen recently approved by
the World Health Organization (WHO). The rapid detection of
second-line drug resistance is important to ensure effective drugs
are used, to prevent the development of extensively drug-resistant
TB (XDR-TB), and to prevent onward transmission.
Historically the gold standard drug resistance test has been
culture-based phenotypic drug sensitivity testing (DST). However
DST for second-line drugs is slow, usually taking weeks, and is not
internationally standardized; the results can be poorly reproduc-
ible. Several rapid molecular tests, performed directly on clinical
samples and giving results within hours, are available to detect
resistance. Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is an
automated PCR test that detects rifampicin resistance and was
endorsed by the WHO in 2010. The WHO has also endorsed line
probe assays (LPAs) including GenoType MTBDRsl (Hainciety for Infectious Diseases. This is an open access article under the CC BY license
C. Nimmo et al. / International Journal of Infectious Diseases 62 (2017) 44–46 45Lifescience, Nehren, Germany), which detects several speciﬁc
resistance mutations for three drug groups including aminoglyco-
sides and ﬂuoroquinolones. However, these rapid molecular tests
are limited to testing predetermined drug resistance mutations.
The most recent GenoType MTBDRsl v2.0 can test for resistance at
10 different mutation sites, while online databases now include
over 1000 drug resistance mutations.
Mycobacterial whole genome sequencing (WGS) can provide a
complete genetic resistance proﬁle for all known drug resistance
mutations by referencing regularly updated resistance databases.
Unlike existing rapid molecular tests, it can differentiate synony-
mous from non-synonymous mutations by excluding mutations
that will not cause an amino acid change. However, WGS generally
requires an initial culture stage to ensure enough mycobacterial
DNA, as it relies on having sufﬁcient good quality DNA to provide
adequate genome coverage depth. This introduces delays that can
have signiﬁcant clinical implications. Mycobacterial DNA from
early MGIT culture (Mycobacterial Growth Incubator Tube; BD
Diagnostics, Franklin Lakes, NJ, USA) has been used to speed up the
time from sample receipt to result to a theoretical 9 days
(Pankhurst et al., 2016). WGS directly from unenhanced clinical
samples such as sputum has previously yielded low quality DNA
that is unsuitable for diagnostics, although this is improved with a
human DNA depletion step. A recent study showed that this
produced drug resistance information for 24 out of 40 mostly
smear-positive samples (Votintseva et al., 2017).
The present authors have previously reported the use of the
oligonucleotide enrichment technology SureSelectXT (Agilent,
Santa Clara, CA, USA) to obtain Mycobacterium tuberculosis DNA
directly from smear-positive and smear-negative sputum samples
(Brown et al., 2015), avoiding the need for the initial culture step, to
provide WGS data in 20 of 24 smear-positive samples within 96 h.
A clinical case where WGS directly from sputum provided a drug
resistance proﬁle in a clinically relevant timeframe and altered
patient management before alternative testing results were
available is reported here.Table 1
Resistance patterns identiﬁed by Xpert MTB/RIF, GenoType MTBDRplus, GenoType MT
University College London), and phenotypic testing (performed at NMRS). Mutations ide
the number of days for results to be reported to clinicians following receipt in the labo
Xpert MTB/
RIF
MTBDRplus
v1.0
MTBDRsl v1.0 
Days to result 0 0 1 
Rifampicin Resistant
rpoB
Resistant
rpoB H526Y
– 
Isoniazid – Resistant
fabG1/inhA
C-15T
– 
Pyrazinamide – – – 
Ethambutol – – Wild-type 
Moxiﬂoxacin – – Initial: wild-type/resistant gyrA
D94G
Repeat: wild-type
Oﬂoxacin – – 
Amikacin – – Wild-type 
Kanamycin – – Wild-type 
PAS – – – 
Prothionamide – – – 
Capreomycin – – – 
Linezolid – – – 
Streptomycin – – – 
NMRS, National Mycobacterial Reference Service.
a Excluding delays from batching.
b Number of days for phenotypic sensitivity to each drug indicated in brackets.Case report
A 29-year-old Nigerian woman presented to the emergency
department with a 6-month history of cough and night sweats. She
had been diagnosed with presumed pulmonary TB in Nigeria 3
years previously, where she had been treated empirically with
rifampicin, isoniazid, pyrazinamide, and ethambutol for 9 months.
Initial induced sputum samples were positive for acid-fast
bacilli (AFB) on microscopy. Xpert MTB/RIF, done on all smear-
positive samples, conﬁrmed a rpoB mutation highly suggestive of
rifampicin resistance and likely MDR-TB. Sputum samples were
sent directly to the National Mycobacterial Reference Service
(NMRS) for genotypic resistance testing with commercially
available kits and to University College London (UCL) for direct
enrichment WGS. Sputum samples were inoculated into MGIT and
when these ﬂagged positive, mycobacterial isolates were sent to
NMRS for ﬁrst- and second-line phenotypic DST and to UCL for
additional WGS. Resistance results and time to identiﬁcation are
shown in Table 1.
Rifampicin resistance was conﬁrmed by Hain LPA (GenoType
MDRTBplus v1.0) and WGS on direct samples. The LPA reported a C-
15T mutation in the fabG1/inhA promoter, which has a strong
association with intermediate isoniazid resistance and ethion-
amide resistance. WGS testing also identiﬁed the inhA S94A
mutation, which is also associated with isoniazid and ethionamide
resistance, but is not detected by Hain LPAs. Importantly the
combination of C-15T and S94A has been reported to be linked to
high-level isoniazid resistance (Machado et al., 2013), and this was
subsequently conﬁrmed on phenotypic DST. The Hain LPA for
second-line drugs (GenoType MDRTBsl v1.0) initially reported a
mixed genotype suggestive of ﬂuoroquinolone resistance (Table 1),
with weak hybridization of the mutant probe at the gyrA D94G
locus.
Based on the LPA results, the patient was initially started on
moxiﬂoxacin, amikacin, cycloserine, linezolid, pyrazinamide,
ethambutol, and high-dose isoniazid, pending conﬁrmation ofBDRsl (performed at NMRS), SureSelectXT WGS, MGIT culture WGS (performed at
ntiﬁed are stated underneath genotypic resistance results. ‘Days to result’ indicates
ratory. A dash () indicates a drug not tested with the assay indicated.
SureSelectXT
(WGS)
MGIT culture (WGS) Phenotypic
5a 17 29–119b
Resistant
rpoB H526Y
Resistant
rpoB H526Y
Highly resistant
(62 days)
Resistant
fabG1/inhA C-15T
inhA S94A
Resistant
fabG1/inhA C-15T
inhA S94A
Highly resistant
(29 days)
Wild-type Wild-type Sensitive (29 days)
Wild-type/
resistant
embB G406D
Wild-type Sensitive (29 days)
Wild-type Wild-type Sensitive (79 days)
Sensitive (79 days)
Wild-type Wild-type Sensitive (79 days)
Wild-type Wild-type Sensitive (79 days)
Wild-type Wild-type Sensitive (97 days)
Resistant
fabG1/inhA C-15T
inhA S94A
Resistant
fabG1/inhA C-15T
inhA S94A
Resistant (119 days)
Wild-type Wild-type Sensitive (79 days)
Wild-type Wild-type Sensitive (79 days)
Resistant
gid G34D
Not detected (insufﬁcient
coverage)
–
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reassurance that the isolate was sensitive to ﬂuoroquinolones,
pyrazinamide, and other drugs used for MDR-TB within 10 days of
sample collection (including a 5-day delay due to batching), 12
days before WGS from MGIT samples and 19–109 days before
phenotypic DST results. The WHO-approved 9-month MDR-TB
regimen was not used given genotypic evidence of high-level
isoniazid and ethionamide resistance, the presence of sufﬁcient
alternative effective drugs, and to minimize toxicity.
High-dose isoniazid was stopped, as the combination of inhA
mutations detected on WGS conferred high resistance, one of
which was not tested on LPA. This was an important change, as
isoniazid and cycloserine when given concurrently have an
increased risk of neurotoxicity. A repeat Hain second-line drug
LPA conﬁrmed wild-type gyrA gene.
WGS on the direct sputum sample also reported a mutation
consistent with weak ethambutol resistance that was not
identiﬁed by the LPAs. Repeat WGS on a second sputum sample
showed a mixed bacterial population, where 50% of sequencing
reads held this mutation and the rest not. This may represent
heteroresistance (Eilertson et al., 2014).
A repeat sputum sample sent on day 60 was AFB-negative on
smear microscopy and culture. The patient has now completed 18
months of treatment without relapse.
Discussion
The case presented herein demonstrates that WGS can be
successfully performed directly from sputum and can identify
more second-line drug resistance in a clinically useful timeframe
than other currently available methods. While rapid tests such as
the Xpert MTB/RIF and LPAs are helpful, the former is limited to
mutations in the rpoB gene, while the latter relies on probe
hybridization, and they are therefore inherently limited in the
number of mutations assessed. Mutations detected at resistance
loci not causing an amino acid change and synonymous
substitutions have also been incorrectly reported as conferring
resistance. WGS is potentially more accurate by allowing scrutiny
and interpretation of the exact substitution, as occurred in this case
where ﬂuoroquinolone resistance was incorrectly suggested by
LPA, and provides a rapid, complete genetic drug resistance proﬁle.
WGS directly from sputum thus promises rapid detection of
drug resistance within a clinically relevant timeframe. This could
enable early selection of personalized drug treatment, which may
be of particular relevance in regions with high rates of second-line
drug resistance.Funding
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